H.C. Wainwright Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...
Hosted on MSN1d
Scotiabank Initiates Coverage of Viking Therapeutics (VKTX) with Sector Outperform Recommendation
Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...
Scotiabank starts Viking Therapeutics at Outperform, sees attractive entry point
As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...
U.S. investors, Big Pharma race to find new medicines in China
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
Wall Street Journal3d
Summit Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Barron's3d
Viking Therapeutics Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Viking Therapeutics VKTX has outperformed the market over the past 5 years by 22.07% on an annualized basis producing an ...
Why Viking Therapeutics Inc. (VKTX) Went Down on Monday
Viking Therapeutics Inc. dropped its share prices by 7.34 percent on Monday to end at $30.17 apiece as investors reacted ...